Effectiveness of montelukast for uremic pruritus in hemodialysis patients: A protocol for systematic review and meta-analysis

• Published in: Medicine (Baltimore) 2020-11, Vol.99 (46), p.e23229-e23229
• Main Authors: Gao, Chao-qing, Zhou, Jia-jun, Tan, Ya-yin, Tong, Chang-jun
• Format: Article
• Language: English
• Subjects: Acetates - therapeutic use; Clinical Protocols; Cyclopropanes; Humans; Kidney Failure, Chronic - complications; Kidney Failure, Chronic - drug therapy; Leukotriene Antagonists - therapeutic use; Meta-Analysis as Topic; Pruritus - drug therapy; Pruritus - physiopathology; Quinolines - therapeutic use; Renal Dialysis - methods; Study Protocol Systematic Review; Sulfides; Systematic Reviews as Topic
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000023229

Uremic pruritus (UP) is a common and tormenting symptom in end-stage renal disease patients undergoing maintenance hemodialysis. An increasing number of studies have been published in recent years to support the effectiveness of montelukast for UP. We will conduct a comprehensive systematic review and meta-analysis to evaluate effectiveness of montelukast for UP in hemodialysis patients. The following electronic databases were searched: Pubmed, Embase, Web of Science, Cochrane Library, the China National Knowledge Infrastructure, Chinese Biomedical Literature Database, and China Science and Technology Journal Database. The range of publication time was from the inception of the database to December 2020. Two reviewers will independently conduct article selection, data collection, and assessment of risk of bias. Any disagreement will be resolved by discussion with the third reviewer. Meta-analysis will be performed by Review Manager 5.3. The Cochrane Collaboration tool will be used to assess the risk of bias. This study will provide a systematic synthesis of current published data to explore the effectiveness of montelukast for UP in hemodialysis patients. This systematic review and meta-analysis will provide clinical evidence for the effectiveness of montelukast for UP in hemodialysis patients and inform our understanding of the value of montelukast in improving pruritus symptoms. This study will help clinicians, patients, and policy makers to make better decisions regarding the appropriate role of montelukast as a part of patient management routines. INPLASY2020100043.